MED1 and breast carcinoma: Importantly, the activation of MED1 has been shown to correlate with poor clinical outcomes in breast cancer patients treated with endocrine therapy[33] and our results indicate that trastuzumab and fulvestrant may improve the prognosis of HR+/HER2+ breast cancer patients by inhibiting the activation of MED1.